The Healthy Activity Program (HAP), a lay counsellor-delivered brief psychological treatment for severe depression, in primary care in India: a randomised controlled trial

Vikram Patel, Benedict Weobong, Helen A Weiss, Arpita Anand, Bhargav Bhat, Basavraj Katti, Sona Dimidjian, Ricardo Araya, Steve D Hollon, Michael King, Lakshmi Vijayakumar, A-La Park, David McDaid, Terry Wilson, Richard Velleman, Betty R Kirkwood, Christopher G Fairburn, Vikram Patel, Benedict Weobong, Helen A Weiss, Arpita Anand, Bhargav Bhat, Basavraj Katti, Sona Dimidjian, Ricardo Araya, Steve D Hollon, Michael King, Lakshmi Vijayakumar, A-La Park, David McDaid, Terry Wilson, Richard Velleman, Betty R Kirkwood, Christopher G Fairburn

Abstract

Background: Although structured psychological treatments are recommended as first-line interventions for depression, only a small fraction of people globally receive these treatments because of poor access in routine primary care. We assessed the effectiveness and cost-effectiveness of a brief psychological treatment (Healthy Activity Program [HAP]) for delivery by lay counsellors to patients with moderately severe to severe depression in primary health-care settings.

Methods: In this randomised controlled trial, we recruited participants aged 18-65 years scoring more than 14 on the Patient Health Questionnaire 9 (PHQ-9) indicating moderately severe to severe depression from ten primary health centres in Goa, India. Pregnant women or patients who needed urgent medical attention or were unable to communicate clearly were not eligible. Participants were randomly allocated (1:1) to enhanced usual care (EUC) alone or EUC combined with HAP in randomly sized blocks (block size four to six [two to four for men]), stratified by primary health centre and sex, and allocation was concealed with use of sequential numbered opaque envelopes. Physicians providing EUC were masked. Primary outcomes were depression symptom severity on the Beck Depression Inventory version II and remission from depression (PHQ-9 score of <10) at 3 months in the intention-to-treat population, assessed by masked field researchers. Secondary outcomes were disability, days unable to work, behavioural activation, suicidal thoughts or attempts, intimate partner violence, and resource use and costs of illness. We assessed serious adverse events in the per-protocol population. This trial is registered with the ISRCTN registry, number ISRCTN95149997.

Findings: Between Oct 28, 2013, and July 29, 2015, we enrolled and randomly allocated 495 participants (247 [50%] to the EUC plus HAP group [two of whom were subsequently excluded because of protocol violations] and 248 [50%] to the EUC alone group), of whom 466 (95%) completed the 3 month primary outcome assessment (230 [49%] in the EUC plus HAP group and 236 [51%] in the EUC alone group). Participants in the EUC plus HAP group had significantly lower symptom severity (Beck Depression Inventory version II in EUC plus HAP group 19·99 [SD 15·70] vs 27·52 [13·26] in EUC alone group; adjusted mean difference -7·57 [95% CI -10·27 to -4·86]; p<0·0001) and higher remission (147 [64%] of 230 had a PHQ-9 score of <10 in the HAP plus EUC group vs 91 [39%] of 236 in the EUC alone group; adjusted prevalence ratio 1·61 [1·34-1·93]) than did those in the EUC alone group. EUC plus HAP showed better results than did EUC alone for the secondary outcomes of disability (adjusted mean difference -2·73 [-4·39 to -1·06]; p=0·001), days out of work (-2·29 [-3·84 to -0·73]; p=0·004), intimate partner physical violence in women (0·53 [0·29-0·96]; p=0·04), behavioural activation (2·17 [1·34-3·00]; p<0·0001), and suicidal thoughts or attempts (0·61 [0·45-0·83]; p=0·001). The incremental cost per quality-adjusted life-year gained was $9333 (95% CI 3862-28 169; 2015 international dollars), with an 87% chance of being cost-effective in the study setting. Serious adverse events were infrequent and similar between groups (nine [4%] in the EUC plus HAP group vs ten [4%] in the EUC alone group; p=1·00).

Interpretation: HAP delivered by lay counsellors plus EUC was better than EUC alone was for patients with moderately severe to severe depression in routine primary care in Goa, India. HAP was readily accepted by this previously untreated population and was cost-effective in this setting. HAP could be a key strategy to reduce the treatment gap for depressive disorders, the leading mental health disorder worldwide.

Funding: Wellcome Trust.

Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license. Published by Elsevier Ltd.. All rights reserved.

Figures

Figure 1
Figure 1
Trial profile CAP=Counselling for Alcohol Problems. EUC=enhanced usual care. HAP=Healthy Activity Program. PHQ-9=Patient Health Questionnaire 9.
Figure 2
Figure 2
Effect of baseline PHQ-9 score on depression severity according to BDI-II score at 3 months BDI=Beck Depression Inventory. EUC=enhanced usual care. HAP=Healthy Activity Program. PHQ=Patient Health Questionnaire.
Figure 3
Figure 3
Cost-effectiveness acceptability curve: willingness to pay per quality-adjusted life-year gained from the Healthy Activity Program from a health system perspective

References

    1. Patel V, Chisholm D, Parikh R. Addressing the burden of mental, neurological, and substance use disorders: key messages from Disease Control Priorities, 3rd edition. Lancet. 2016;387:1672–1685.
    1. Ferrari AJ, Somerville AJ, Baxter AJ. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychol Med. 2013;43:471–481.
    1. Whiteford HA, Ferrari AJ, Degenhardt L, Feigin V, Vos T. The global burden of mental, neurological and substance use disorders: an analysis from the Global Burden of Disease Study 2010. PLoS One. 2015;10:e0116820.
    1. Chisholm D, Sweeny K, Sheehan P. Scaling-up treatment of depression and anxiety: a global return on investment analysis. Lancet Psychiatry. 2016;3:415–424.
    1. Cuijpers P, Hollon SD, van Straten A, Bockting C, Berking M, Andersson G. Does cognitive behaviour therapy have an enduring effect that is superior to keeping patients on continuation pharmacotherapy? A meta-analysis. BMJ Open. 2013;3:4.
    1. WHO . mhGAP. Mental Health Gap Action Programme. Scaling up care for mental, neurological and substance use disorders. World Health Organization; Geneva: 2008.
    1. Patel V, Xiao S, Chen H. The magnitude of and health system responses to the mental health treatment gap in adults in India and China. Lancet. 2016 published online May 17.
    1. Wang PS, Aguilar-Gaxiola S, Alonso J. Use of mental health services for anxiety, mood, and substance disorders in 17 countries in the WHO world mental health surveys. Lancet. 2007;370:841–850.
    1. Maziak W, Eissenberg T, Klesges RC, Keil U, Ward KD. Adapting smoking cessation interventions for developing countries: a model for the Middle East. Int J Tuberc Lung Dis. 2004;8:403–413.
    1. Patel V. The need for treatment evidence for common mental disorders in developing countries. Psychol Med. 2000;30:743–746.
    1. van Ginneken N, Tharyan P, Lewin S. Non-specialist health worker interventions for the care of mental, neurological and substance-abuse disorders in low- and middle-income countries. Cochrane Database Syst Rev. 2013;11 CD009149.
    1. Collins PY, Patel V, Joestl SS. Grand challenges in global mental health. Nature. 2011;475:27–30.
    1. Chowdhary N, Anand A, Dimidjian S. The Healthy Activity Program lay counsellor delivered treatment for severe depression in India: systematic development and randomised evaluation. Br J Psychiatry. 2016;208:381–388.
    1. Vellakkal S, Patel V. Designing psychological treatments for scalability: the PREMIUM approach. PLoS One. 2015;10:e0134189.
    1. Nadkarni A, Velleman R, Dabholkar H. The systematic development and pilot randomized evaluation of counselling for alcohol problems, a lay counselor-delivered psychological treatment for harmful drinking in primary care in India: the PREMIUM study. Alcohol Clin Exp Res. 2015;39:522–531.
    1. WHO . mhGAP intervention guide for mental, neurological and substance use disorders in non-specialized health settings: mental health Gap Action Programme (mhGAP) World Health Organization; Geneva: 2010.
    1. Dimidjian S, Barrera M, Jr, Martell C, Munoz RF, Lewinsohn PM. The origins and current status of behavioral activation treatments for depression. Annu Rev Clin Psychol. 2011;7:1–38.
    1. Nadkarni A, Weobong B, Weiss HA. Counselling for Alcohol Problems (CAP), a lay counsellor-delivered brief psychological treatment for harmful drinking in men, in primary care in India: a randomised controlled trial. Lancet. 2016 published online Dec 14.
    1. Patel V, Araya R, Chowdhary N. Detecting common mental disorders in primary care in India: a comparison of five screening questionnaires. Psychol Med. 2008;38:221–228.
    1. Patel V, Weobong B, Nadkarni A. The effectiveness and cost-effectiveness of lay counsellor-delivered psychological treatments for harmful and dependent drinking and moderate to severe depression in primary care in India: PREMIUM study protocol for randomized controlled trials. Trials. 2014;15:101.
    1. Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering. Lancet. 2002;359:614–618.
    1. Fournier JC, DeRubeis RJ, Shelton RC, Hollon SD, Amsterdam JD, Gallop R. Prediction of response to medication and cognitive therapy in the treatment of moderate to severe depression. J Consult Clin Psychol. 2009;77:775–787.
    1. Kraemer HC. Messages for clinicians: moderators and mediators of treatment outcome in randomized clinical trials. Am J Psychiatry. 2016;173:672–679.
    1. Aggarwal NK, Balaji M, Kumar S. Using consumer perspectives to inform the cultural adaptation of psychological treatments for depression: a mixed methods study from south Asia. J Affect Disord. 2014;163:88–101.
    1. Hopko DR, Ryba MM, McIndoo C, File A. Behavioral activation. In: Nezu CM, Nezu AM, editors. The Oxford Handbook of Cognitive and Behavioral Therapies. Oxford University Press; New York: 2015.
    1. Singla DR, Weobong B, Nadkarni A. Improving the scalability of psychological treatments in developing countries: an evaluation of peer-led therapy quality assessment in Goa, India. Behav Res Ther. 2014;60:53–59.
    1. Chisholm D, Knapp MR, Knudsen HC, Amaddeo F, Gaite L, van Wijngaarden B. Client Socio-Demographic and Service Receipt Inventory—European Version: development of an instrument for international research. EPSILON Study 5. European Psychiatric Services: inputs linked to outcome domains and needs. Br J Psychiatry Suppl. 2000;39:s28–s33.
    1. Localio AR, Margolis DJ, Berlin JA. Relative risks and confidence intervals were easily computed indirectly from multivariable logistic regression. J Clin Epidemiol. 2007;60:874–882.
    1. Hewitt CE, Torgerson DJ, Miles JN. Is there another way to take account of noncompliance in randomized controlled trials? CMAJ. 2006;175:347.
    1. Sterne JA, Davey Smith G. Sifting the evidence—what's wrong with significance tests? BMJ. 2001;322:226–231.
    1. Burtoff C, Hock RS, Weiss HA. Economic evaluation of a task-shifting intervention for common mental disorders in India. Bull World Health Organ. 2012;90:813–821.
    1. WHO . Mental illness in general health care: an international study. John Wiley and Sons; Chichester: 1995.
    1. Tan-Torres T, Baltussen R, Adam T. Making choices in health: WHO guide to cost effectiveness analysis. World Health Organization; Geneva: 2003.
    1. Minsitry of Statistics and Programme Implementation State Domestic Product and other aggregates, 2011–2012 series. Feb 29, 2016. (accessed May 5, 2016).
    1. Minimum wage in Goa with effect from May 1, 2016. (accessed May 5, 2016).
    1. Driessen E, Hollon SD. Cognitive behavioral therapy for mood disorders: efficacy, moderators and mediators. Psychiatr Clin North Am. 2010;33:537–555.
    1. Patel V, Weiss HA, Chowdhary N. Effectiveness of an intervention led by lay health counsellors for depressive and anxiety disorders in primary care in Goa, India (MANAS): a cluster randomised controlled trial. Lancet. 2010;376:2086–2095.
    1. Patel V, Kirkwood BR, Pednekar S. Gender disadvantage and reproductive health risk factors for common mental disorders in women: a community survey in India. Arch Gen Psychiatry. 2006;63:404–413.
    1. Cuijpers P, Smit F, Bohlmeijer E, Hollon SD, Andersson G. Efficacy of cognitive-behavioural therapy and other psychological treatments for adult depression: meta-analytic study of publication bias. Br J Psychiatry. 2010;196:173–178.
    1. Bower P, Kontopantelis E, Sutton A. Influence of initial severity of depression on effectiveness of low intensity interventions: meta-analysis of individual patient data. BMJ. 2013;346:f540.
    1. Steer RA, Brown GK, Beck AT, Sanderson WC. Mean Beck Depression Inventory-II scores by severity of major depressive episode. Psychol Rep. 2001;88(3 pt 2):1075–1076.
    1. Richards DA, Ekers D, McMillan D. Cost and outcome of behavioural activation versus cognitive behavioural therapy for depression (COBRA): a randomised, controlled, non-inferiority trial. Lancet. 2016;388:871–880.
    1. Patel V, Pereira J, Mann A. Somatic and psychological models of common mental disorders in India. Psychol Med. 1998;28:135–143.
    1. Patel V, Pereira J, Coutinho L, Fernandes R, Fernandes J, Mann A. Poverty, psychological disorder and disability in primary care attenders in Goa, India. Br J Psychiatry. 1998;171:533–536.
    1. PREMIUM counselling relationship. (accessed Nov 17, 2016).
    1. PREMIUM Healthy Activity Program. (accessed Nov 17, 2016).
    1. Sangath Goa PREMIUM. Nov 22, 2016. (accessed Nov 27, 2016).

Source: PubMed

Подписаться